Pharmacophore models for GABAA modulators: Implications in CNS drug discovery

Expert Opinion on Drug Discovery

Volumn 5, Issue 5, 2010, Pages 441-460

  Ghoshal, Nanda ^a   Vijayan, R Suyambu Kesava ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

Benzodiazepines; GABA; GABAA; Pharmacophore; QSAR; SAR

Indexed keywords

3 HYDROXY 5 (4 PIPERIDYL)ISOXAZOLE; 3 METHYL 6 (3 TRIFLUOROMETHYLPHENYL) 1,2,4 TRIAZOLO[4,3 B]PYRIDAZINE; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; 4 AMINOBUTYRIC ACID DERIVATIVE; 4 AMINOCROTONIC ACID; 6 BROMOFLAVONE; 6 ETHYLFLAVONE; 6 METHYLFLAVONE; ARECAIDINE; BENZODIAZEPINE DERIVATIVE; CENTRAL NERVOUS SYSTEM AGENTS; CHLORDIAZEPOXIDE; DIAZEPAM; DIHYDROMUSCIMOL; FLAVONE DERIVATIVE; FLAVONOID; GABOXADOL; IMIDAZOLE DERIVATIVE; MUSCIMOL; PROPYLFLAVONE; QUINOLONE DERIVATIVE; RY 80; SULFONIC ACID DERIVATIVE; THIOMUSCIMOL; UNCLASSIFIED DRUG; ZOLPIDEM;

DRUG BINDING SITE; DRUG RESEARCH; DRUG STRUCTURE; MATHEMATICAL MODEL; PHARMACOPHORE; PRIORITY JOURNAL; REVIEW;

EID: 77951668877     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441003789363     Document Type: Review

References (301)

1. Korpi ER, Grunder G, Luddens H. Drug interactions at GABAA receptors. Prog Neurobiol 2002;67(2):113-159
2. Thomsen C, Ebert B. Modulators of the GABA receptor. Novel therapeutic prospects. Glutamate and GABA receptors and transporters. Structure, function and pharmacology. Taylor & Francis, New York; 2002. p. 407-427
3. Connolly CN, Wafford KA. The Cys-loop superfamily of ligand-gated ion channels: the impact of receptor structure on function. Biochem Soc Trans 2004;32(Pt3):529-534
4. Mehta AK, Ticku MK. An update on GABAA receptors. Brain Res Brain Res Rev 1999;29(2-3):196-217
5. Ostermeier C, Michel H. Crystallization of membrane proteins. Curr Opin Struct Biol 1997;7(5):697-701
6. Ernst M, Bruckner S, Boresch S, Sieghart W. Comparative models of GABAA receptor extracellular and transmembrane domains: important insights in pharmacology and function. Mol Pharmacol 2005;68(5):1291-1300
7. O'Mara M, Cromer B, Parker M, Chung SH. Homology model of the GABAA receptor examined using brownian dynamics. Biophys J 2005;88(5):3286-3299
8. Campagna-Slater V, Weaver DF. Molecular modelling of the GABAA ion channel protein. J Mol Graph Model 2007;25(5):721-730
9. Vijayan RS, Bera I, Prabu M, et al. Combinatorial library enumeration and lead hopping using comparative interaction fingerprint analysis and classical 2D QSAR methods for seeking novel GABA(A) alpha(3) modulators. J Chem Inf Model 2009;49(11):2498-2511
10. Krogsgaard-Larsen P, Frølund B, Liljefors T. Specific GABA (A) agonists and partial agonists. Chem Rec 2002;2(6):419-430
11. Clayton T, Chen JL, Ernst M, et al. An updated unified pharmacophore model of the benzodiazepine binding site on gamma-aminobutyric acid(a) receptors: correlation with comparative models. Curr Med Chem 2007;14(26):2755-2775
12. Mori A, Kosaka M. Incorporation of gamma-aminobutyric acid (GABA) in the brain and internal organs of mice. Psychiatry Clin Neurosci 1961;15:92-97
13. Krogsgaard-Larsen P, Johnston GA, Curtis DR, et al. Structure and biological activity of a series of conformationally restricted analogues of GABA. J Neurochem 1975;25(6):803-809
14. Curtins DR, Watkins JC. The excitation and depression of spinal neurones by structurally related amino acids. J Neurochem 1960;6:117-141
15. McGeer EG, McGeer PL, McLennan H. The inhibitory action of 3-hydroxytyramine, gamma-aminobutyric acid(GABA) and some other compounds towards the crayfish stretch receptor neuron. J Neurochem 1961;8(1):36-49
16. Lorenzini ML, Bruno-Blanch L, Estiu GL. Structural and electronic factors associated with the activity in the GABA-A system. J Mol Struct: THEOCHEM 1998;454(1):1-16
17. Man RD, Johnston GAR. Synthetic analogs for the study of GABA as a neurotransmitter. Med Res Rev 1983;3(2):91-118
18. Luzzi S, Maggi CA, Spagnesi S, et al. 5-Aminovaleric acid interactions with GABAA and GABAB receptors in guinea-pig ileum. J Auton Pharmacol 1985;5(1):65-69
19. Galli A, Zilletti L, Scotton M, et al. Inhibition of Na+-independent [3H] GABA binding to synaptic membranes of rat brain by beta-substituted GABA derivatives. J Neurochem 1979;32(3): 1123-1125
20. Curtis DR, Watkins JC. The pharmacology of amino acids related to gamma-aminobutyric acid. Pharmacol Rev 1965;17(4):347-391
21. Curtis DR, Watkins JC. The excitation and depression of spinal neurones by structurally related amino acids. J Neurochem 1960;6:117-141
22. Krogsgaard-Larsen P, Jacobsen P, Falch E. The GABA receptors, In: Enna SJ, editor, Humana, New Jersey; 1983. p. 149
23. Galzigna L, Manani G, Garbin L, et al. Different action of two hydrophobic 4-aminobutyric acid derivatives on the whole animal and on isolated tissues. Agressologie 1981;22(5):219-224
24. Wermuth CG, Biziere K. Pyridazyl-GABA derivatives: a new class of synthetic GABAA antagonists. Trends Pharm Sci 1986;7:721-724
25. Johnston GAR, Kerr DIB, Ong J. In: Rand MJ, Raper C, editors, Pharmacology. Elsevier, Amsterdam; 1987. p. 121
26. Allan RD, Dickenson HW, Hiern BP, et al. Isothiouronium compounds as gamma-aminobutyric acid agonists. Br J Pharmacol 1986;88(2):379-387
27. Chilton WS, Ott J. Toxic metabolites of Amanita pantherina, A. cothurnata, A. muscaria and other Amanita species. Lloydia 1976;39(2-3):150-157
28. Krogsgaard-Larsen P, Hjeds H, Curtis DR, et al. Glycine antagonists structurally related to muscimol, THIP, or isoguvacine. J Neurochem 1982;39(5):1319-1324
29. Krogsgaard-Larsen P, Hjeds H, Curtis DR, et al. Dihydromuscimol, thiomuscimol and related heterocyclic compounds as GABA analogues. J Neurochem 1979;32:1717-1724
30. Frey M, Jager V. Synthesis of N-substituted muscimol derivatives including N-glycylmuscimol. Synthesis 1985(12);1100-1104
31. Aprison MH, Lipkowitz KB. Muscimol and N,N-dimethylmuscimol: from a GABA agonist to a glycine antagonist. J Neurosci Res 1992;31(1):166-174
32. Krogsgaard-Larsen P, Johnston GA, Lodge D, Curtis DR. A new class of GABA agonist. Nature 1977;268(5615):53-55
33. Kjaer M, Nielsen H. The analgesic effect of the GABA-agonist THIP in patients with chronic pain of malignant origin. A phase-1-2 study. Br J Clin Pharmacol 1983;16(5):477-485
34. Vaught JL, Pelley K, Costa LG, et al. A comparison of the antinociceptive responses to the GABA-receptor agonists THIP and baclofen. Neuropharmacology 1985;24(3):211-216
35. Falch E, Jacobsen P, Krogsgaard-Larsen P, Curtis DR. GABA-mimetic activity and effects on diazepam binding of aminosulphonic acids structurally related to piperidine-4-sulphonic acid. J Neurochem 1985;44(1):68-75
36. Krogsgaard-Larsen P, Mikkelsen H, Jacobsen P, et al. 4,5,6,7- Tetrahydroisothiazolo[5,4-c]pyridin-3-ol and related analogues of THIP. Synthesis and biological activity. J Med Chem 1983;26(6):895-900
37. Frølund B, Kristiansen U, Brehm L, et al. Partial GABAA receptor agonists. Synthesis and in vitro pharmacology of a series of nonannulated analogs of 4,5,6,7-tetrahydroisoxazolo[4,5-c]pyridin-3-ol. J Med Chem 1995;38(17):3287-3296
38. Frølund B, Jørgensen AT, Tagmose L, et al. Novel class of potent 4-arylalkyl substituted 3-isoxazolol GABAA antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem 2002;45(12):2454-2468
39. Krogsgaard-Larsen P, Fround B, Jrogensen SF, Schousboe A. GABAA receptor agonists, partial agonists, and antagonists. Design and therapeutic prospects. J Med Chem 1994;37(16):2489-2505
40. Krehan D, Storustovu SI, Liljefors T, et al. Potent 4-arylalkyl- substituted 3-isothiazolol GABA(A) competitive/noncompetitive antagonists: synthesis and pharmacology. J Med Chem 2006;49(4):1388-1396
41. Newell JG, Czajkowski C. The GABAA receptor alpha 1 subunit Pro174-Asp191 segment is involved in GABA binding and channel gating. J Biol Chem 2003;278(15):13166-13172
42. Boileau AJ, Newell JG, Czajkowski C. GABA(A) receptor beta 2 Tyr97 and Leu99 line the GABA-binding site. Insights into mechanisms of agonist and antagonist actions. J Biol Chem 2002;277(4):2931-2937
43. Mercado J, Czajkowski C. Charged residues in the alpha1 and beta2 pre-M1 regions involved in GABAA receptor activation. J Neurosci 2006;26(7):2031-2040
44. Wagner DA, Czajkowski C. Structure and dynamics of the GABA binding pocket: a narrowing cleft that constricts during activation. J Neurosci 2001;21(1):67-74
45. Westh-Hansen SE, Witt MR, Dekermendjian K, et al. Arginine residue 120 of the human GABAA receptor alpha 1, subunit is essential for GABA binding and chloride ion current gating. NeuroReport 1999;10(11):2417-2421
46. Wagner DA, Czajkowski C, Jone MV. An arginine involved in GABA binding and unbinding but not gating of the GABAA receptor. J Neurosci 2004;24(11):2733-2741
47. Korpi ER, Gründer G, Lüddens H. Drug interactions at GABAA receptors. Prog Neurobiol 2002;67(2):113-159
48. Choh DW, Farb DH, Fischbach GD. Chlordiazepoxide selectively augments GABA action in spinal cord cell cultures. Nature 1977;269(5626):342-344
49. Randall LO, Schallek W, Heuse GA, et al. The psychosedative properties of methaminodiazepoxide. J Pharmacol Exp Ther 1960;129:163-171
50. Squires RF, Brastrup C. Benzodiazepine receptors in rat brain. Nature 1977;266(5604):732-734
51. Sieghart W, Ernst M. Heterogeneity of GABAA receptors: revived interest in the development of subtype-selective drugs. Curr Med Chem Cent Nervous Syst Agents 2005;5(3):217-242
52. Crippen GM. Distance geometry analysis of the benzodiazepine binding site. Mol Pharmacol 1981;22(1):11-19
53. Codding PW, Muir AKS. Molecular structure of Ro 15-1788 and a model for the binding of benzodiazepine receptor ligands. Mol Pharmacol 1985;28(2):178-184
54. Tebib S, Bourguignon JJ, Wermuth CG. The active analog approach applied to the pharmacophore identification of benzodiazepine receptor ligands. J Comput Aided Mol Des 1987;1(2):153-170
55. Fryer RI. Ligand interactions at the benzodiazepine receptor. In: Emmett J, editor, Comprehensive medicinal chemistry. Pergamon Press, Oxford, UK; 1989. p. 539-566
56. Borea PA, Gilli G, Bertolasi V, Ferretti V. Stereochemical features controlling binding and intrinsic activity properties of benzodiazepine-receptor ligands. Mol Pharmacol 1987;31(4):334-344
57. Allen MS, Tan YC, Trudell ML, et al. Synthetic and computer-assisted analyses of the pharmacophore for the benzodiazepine receptor inverse agonist site. J Med Chem 1990;33(9):2343-2357
58. Zhang W, Koehler KF, Zhang P, Cook JM. Development of a comprehensive pharmacophore model for the benzodiazepine receptor. Drug Des Discov 1995;12(3):193-248
59. Zhang W, Diaz-Arauzo H, Allen MS, et al. Chemical and computer assisted development of the inclusive pharmacophore of benzodiazepine receptors. In: Choudhary MI, editor, Studies in medicinal chemistry. Harwood Academic Publisher, Amsterdam, 1996
60. Wisden W, Laurie DJ, Monyer H, Seeburg PH. The distribution of 13 GABAA receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon. J Neurosci 1992;12(3):1040-1062
61. Wong G, Skolnick P. High affinity ligands for 'diazepam-insensitive' benzodiazepine receptors. Eur J Pharmacol 1992;225(1):63-68
62. Wong G, Koehler KF, Skolnick P, et al. Synthetic and computer-assisted analysis of the structural requirements for selective, high-affinity ligand binding to diazepam-insensitive benzodiazepine receptors. J Med Chem 1993;36(13):1820-1830
63. He X, Huang Q, Ma C, et al. Pharmacophore/receptor models for GABA(A)/BzR alpha2beta3gamma2, alpha3beta3gamma2 and alpha4beta3gamma2 recombinant subtypes. Included volume analysis and comparison to alpha1beta3gamma2, alpha5beta3gamma2, and alpha6beta3gamma2 subtypes. Drug Des Discov 2000;17(2):131-171
64. Dekermendjian K, Kahnberg P, Witt MR, et al. Structure-activity relationships and molecular modeling analysis of flavonoids binding to the benzodiazepine site of the rat brain GABAA receptor complex. J Med Chem 1999;42(21):4343-4350
65. Kahnberg P, Lager E, Rosenberg C, et al. Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABAA receptor. J Med Chem 2002;45(19):4188-4201
66. Lager E, Andersson P, Nilsson J, et al. 4-Quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABAA receptors. Synthesis, pharmacology, and pharmacophore modeling. J Med Chem 2006;49(8):2526-2533
67. Huang X, Liu T, Gu J, et al. 3D-QSAR model of flavonoids binding at benzodiazepine site in GABAA receptors. J Med Chem 2001;44(12):1883-1891
68. Hong X, Hopfinger AJ. 3D-pharmacophores of flavonoid binding at the benzodiazepine GABAA receptor site using 4D-QSAR analysis. J Chem Inf Comput Sci 2003;43(1):324-336
69. Duchowicz PR, Vitale MG, Castro EA, et al. QSAR modeling of the interaction of flavonoids with GABA(A) receptor. Eur J Med Chem 2008;43(8):1593-1602
70. Goodarzi M, Duchowicz PR, Wu CH, et al. New hybrid genetic based support vector regression as QSAR approach for analyzing flavonoids-GABA (A) complexes. J Chem Inf Model 2009;49(6):1475-1485
71. Harris DL, Loew G. Development and assessment of a 3D pharmacophore for ligand recognition of BDZR/GABAA receptors initiating the anxiolytic response. Bioorg Med Chem 2000;8(11):2527-2538
72. Harris D, Clayton T, Cook J, et al. Selective influence on contextual memory: physiochemical properties associated with selectivity of benzodiazepine ligands at GABAA receptors containing the alpha5 subunit. J Med Chem 2008;51(13):3788-3803
73. Löow K, Crestani F, Keist R, et al. Molecular and neuronal substrate for the selective attenuation of anxiety. Science 2000;290(5489):131-134
74. Kralic JE, Korpi ER, O'Buckley TK, et al. Molecular and pharmacological characterization of GABA(A) receptor alpha1 subunit knockout mice. J Pharmacol Exp Ther 2002;302(3):1037-1045
75. Crestani F, Assandri R, Tauber M, et al. Contribution of the alpha1-GABAA receptor subtype to the pharmacological actions of benzodiazepine site inverse agonists. Neuropharmacology 2002;43(4):679-684
76. Rudolph U, Crestani F, Benke D, et al. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature 1999;401(6755):796-800
77. Goodacre SC, Street LJ, Hallett DJ, et al. Imidazo [1,2-a] pyrimidines as functionally selective and orally bioavailable GABA(A) alpha2/alpha3 binding site agonists for the treatment of anxiety disorders. J Med Chem 2006;49(1):35-38
78. Russell MG, Carling RW, Atack JR, et al. Discovery of functionally selective 7,8,9,10-tetrahydro-7,10-ethano-1,2,4-triazolo[3,4-a]phthalazines as GABAA receptor agonists at the alpha 3 subunit. J Med Chem 2005;48(5):1367-1383
79. Carling RW, Moore KW, Street LJ, et al. 3-Phenyl-6-(2-pyridyl)methyloxy- 1,2,4-triazolo[3,4-a]phthalazines and analogues: high-affinity gamma-aminobutyric acid-A benzodiazepine receptor ligands with alpha 2, alpha 3, and alpha 5-subtype binding selectivity over alpha 1. J Med Chem 2004;47(7):1807-1822
80. Carling RW, Madin A, Guiblin A, et al. 7-(1,1-Dimethylethyl)-6-(2-ethyl- 2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b] pyridazine: a functionally selective gammaaminobutyricacid(A) (GABA(A)) alpha2/alpha3-subtype selective agonist that exhibits potent anxiolytic activity but is not sedating in animal models. J Med Chem 2005;48(23):7089-7092
81. Russell MG, Carling RW, Street LJ, et al. Discovery of imidazo[1,2-b][1,2,4] triazines as GABA(A) alpha2/3 subtype selective agonists for the treatment of anxiety. J Med Chem 2006;49(4):1235-1238
82. Goodacre SC, Hallett DJ, Carling RW, et al. Imidazo[1,2-a]pyrazin-8-ones, imidazo[1,2-d][1,2,4]triazin-8-ones and imidazo[2,1-f][1,2,4]triazin-8-ones as a2/a3 subtype selective GABAA agonists for the treatment of anxiety. Bioorg Med Chem Lett 2006;16(6):1582-1585
83. Goodacre SC, Street LJ, Hallett DJ, et al. Atack, Imidazo[1,2-a] pyrimidines as functionally selective and orally bioavailable GABA(A)alpha2/alpha3 binding site agonists for the treatment of anxiety disorders. J Med Chem 2006;49(1):35-38
84. Huang Q, He X, Ma C, et al. Pharmacophore/receptor models for GABA(A)/BzR subtypes (alpha1beta3gamma2, alpha5beta3gamma2, and alpha6beta3gamma2) via a comprehensive ligand-mapping approach. J Med Chem 2000;43(1):71-95
85. Huang Q, Liu R, Zhang P, et al. Predictive models for GABAA/benzodiazepine receptor subtypes: studies of quantitative structure-activity relationships for imidazobenzodiazepines at five recombinant GABAA/benzodiazepine receptor subtypes [alphaxbeta3gamma2 (x = 1-3, 5, and 6)] via comparative molecular field analysis. J Med Chem 1998;41(21):4130-4142
86. Lu A, Zhou J. Pseudoreceptor models and 3D-QSAR for imidazobenzodiazepines at GABA A/BzR subtypes alpha x beta3gamma2 [x = 1-3, 5, and 6] via flexible atom receptor model. J Chem Inf Comput Sci 2004;44(3):1130-1136
87. Vijayan RS, Ghoshal N. Structural basis for ligand recognition at the benzodiazepine binding site of GABAA alpha 3 receptor, and pharmacophore-based virtual screening approach. J Mol Graph Model 2008;27(3):286-298
88. Kahnberg P, Howard MH, Liljefors T, et al. The use of a pharmacophore model for identification of novel ligands for the benzodiazepine binding site of the GABAA receptor. J Mol Graph Model 2004;23(3):253-261
89. Cox ED, Diaz-Arauzo H, Huang Q, et al. Synthesis and evaluation of analogues of the partial agonist 6-(propyloxy)-4-(methoxymethyl)-beta-carboline- 3-carboxylic acid ethylester (6-PBC) and the full agonist 6-(benzyloxy)-4- (methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester (Zk 93423) at wild type and recombinant GABAA receptors. J Med Chem 1998;41(14):2537-2552
90. Valant C, Gregory KJ, Hall NE, et al. A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand. J Biol Chem 2008;283(43):29312-29321
91. Zhou S, Chan E, Pan SQ, et al. Pharmacokinetic interactions of drugs with St John's wort. J Psychopharmacol 2004;18(2):262-276
92. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006;61(3):246-255
93. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003;31(7):815-832
94. Yamamoto T, Suzuki A, Kohno Y. High-throughput screening for the assessment of time-dependent inhibitions of new drug candidates on recombinant CYP2D6 and CYP3A4 using a single concentration method. Xenobiotica 2004;34(1):87-101
95. White RE. High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery. Annu Rev Pharmacol Toxicol 2000;40:133-157
96. Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 1996;59(1):7-13
97. Lee CR, Thrasher KA. Difficulties in anticoagulation management during coadministration of warfarin and rifampin. Pharmacotherapy 2001;21(10):1240-1246
98. Ferslew KE, Hagardorn AN, Harlan GC, McCormick WF. A fatal drug interaction between clozapine and fluoxetine. J Forensic Sci 1998;43(5):1082-1085
99. Kudo K, Imamura T, Jitsufuchi N, et al. Death attributed to the toxic interaction of triazolam, amitriptyline and other psychotropic drugs. Forensic Sci Int 1997;86(1-2):35-41
100. Yao C, Levy RH. Inhibition-based metabolic drug-drug interactions: predictions from in vitro data. J Pharm Sci 2002;91(9):1923-1935
101. Ohno Y, Hisaka A, Suzuki H. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin Pharmacokinet 2007;46(8):681-696
102. Zhou C, Assem M, Tay JC, et al. Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. J Clin Invest 2006;116(6):1703-1712
103. Dickins M. Induction of cytochromes P450. Curr Top Med Chem 2004;4(16):1745-1766
104. Lin JH. CYP induction-mediated drug interactions: in vitro assessment and clinical implications. Pharm Res 2006;23(6):1089-1116
105. Gelboin HV. Benzo[alpha]pyrene metabolism, activation and carcinogenesis: role and regulation of mixed-function oxidases and related enzymes. Physiol Rev 1980;60(4):1107-1166
106. Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998;35(5):361-390
107. Hollenberg PF. Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes. Drug Metab Rev 2002;34(1-2):17-35
108. Obach RS, Walsky RL, Venkatakrishnan K, et al. In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin Pharmacol Ther 2005;78(6):582-592
109. Grime KH, Bird J, Ferguson D, Riley RJ. Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods. Eur J Pharm Sci 2009;36(2-3):175-191
110. Hisaka A, Ohno Y, Yamamoto T, Suzuki H. Prediction of pharmacokinetic drug-drug interaction caused by changes in cytochrome P450 activity using in vivo information. Pharmacol Ther 2010;125(2):230-248
111. Watkins PB, Wrighton SA, Schuetz EG, et al. Macrolide antibiotics inhibit the degradation of the glucocorticoid-responsive cytochrome P-450p in rat hepatocytes in vivo and in primary monolayer culture. J Biol Chem 1986;261(14):6264-6271
112. Ryu DY, Levi PE, Hodgson E. Regulation of hepatic CYP1A isozymes by piperonyl butoxide and acenaphthylene in the mouse. Chem Biol Interact 1997;105(1):53-63
113. Ryu DY, Levi PE, Fernandez-Salguero P, et al. Piperonyl butoxide and acenaphthylene induce cytochrome P450 1A2 and 1B1 mRNA in aromatic hydrocarbon-responsive receptor knock-out mouse liver. Mol Pharmacol 1996;50(3):443-446
114. Raffalli-Mathieu F, Glisovic T, Ben-David Y, Lang MA. Heterogeneous nuclear ribonucleoprotein A1 and regulation of the xenobiotic-inducible gene Cyp2a5. Mol Pharmacol 2002;61(4):795-799
115. Song BJ, Matsunaga T, Hardwick JP, et al. Stabilization of cytochrome P450j messenger ribonucleic acid in the diabetic rat. Mol Endocrinol 1987;1(8):542-547
116. Kliewer SA, Moore JT, Wade L, et al. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 1998;92(1):73-82
117. Bertilsson G, Heidrich J, Svensson K, et al. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci USA 1998;95(21):12208-12213
118. Baes M, Gulick T, Choi HS, et al. A new orphan member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic acid response elements. Mol Cell Biol 1994;14(3):1544-1552
119. Whitlock JP Jr. Induction of cytochrome P4501A1. Annu Rev Pharmacol Toxicol 1999;39:103-125
120. Handschin C, Meyer UA. Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR. Arch Biochem Biophys 2005;433(2):387-396
121. Reschly EJ, Krasowski MD. Evolution and function of the NR1I nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xenobiotics and endogenous compounds. Curr Drug Metab 2006;7(4):349-365
122. Hukkanen J, Vaisanen T, Lassila A, et al. Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells. J Pharmacol Exp Ther 2003;304(2):745-752
123. Wang H, Faucette SR, Gilbert D, et al. Glucocorticoid receptor enhancement of pregnane X receptor-mediated CYP2B6 regulation in primary human hepatocytes. Drug Metab Dispos 2003;31(5):620-630
124. Higashi E, Fukami T, Itoh M, et al. Human CYP2A6 is induced by estrogen via estrogen receptor. Drug Metab Dispos 2007;35(10):1935-1941
125. Jones SA, Moore LB, Shenk JL, et al. The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol Endocrinol 2000;14(1):27-39
126. Stanley LA, Horsburgh BC, Ross J, et al. PXR and CAR: nuclear receptors which play a pivotal role in drug disposition and chemical toxicity. Drug Metab Rev 2006;38(3):515-597
127. Handschin C, Meyer UA. Induction of drug metabolism: the role of nuclear receptors. Pharmacol Rev 2003;55(4):649-673
128. El-Sankary W, Gibson GG, Ayrton A, Plant N. Use of a reporter gene assay to predict and rank the potency and efficacy of CYP3A4 inducers. Drug Metab Dispos 2001;29(11):1499-1504
129. Luo G, Cunningham M, Kim S, et al. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 2002;30(7):795-804
130. Watkins RE, Wisely GB, Moore LB, et al. The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science 2001;292(5525):2329-2333
131. Timsit YE, Negishi M. CAR and PXR: the xenobiotic-sensing receptors. Steroids 2007;72(3):231-246
132. Ung CY, Li H, Yap CW, Chen YZ. In silico prediction of pregnane X receptor activators by machine learning approaches. Mol Pharmacol 2007;71(1):158-168
133. Ekins S, Kortagere S, Iyer M, et al. Challenges predicting ligand-receptor interactions of promiscuous proteins: the nuclear receptor PXR. PLoS Comput Biol 2009;5(12):e1000594
134. Wang H, LeCluyse EL. Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin Pharmacokinet 2003;42(15):1331-1357
135. Koyano S, Kurose K, Saito Y, et al. Functional characterization of four naturally occurring variants of human pregnane X receptor (PXR): one variant causes dramatic loss of both DNA binding activity and the transactivation of the CYP3A4 promoter/enhancer region. Drug Metab Dispos 2004;32(1):149-154
136. Kawana K, Ikuta T, Kobayashi Y, et al. Molecular mechanism of nuclear translocation of an orphan nuclear receptor, SXR. Mol Pharmacol 2003;63(3):524-531
137. Squires EJ, Sueyoshi T, Negishi M. Cytoplasmic localization of pregnane X receptor and ligand-dependent nuclear translocation in mouse liver. J Biol Chem 2004;279(47):49307-49314
138. Hariparsad N, Chu X, Yabut J, et al. Identification of pregnane-X receptor target genes and coactivator and corepressor binding to promoter elements in human hepatocytes. Nucleic Acids Res 2009;37(4):1160-1173
139. Lehmann JM, McKee DD, Watson MA, et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998;102(5):1016-1023
140. Goodwin B, Hodgson E, Liddle C. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmacol 1999;56(6):1329-1339
141. Goodwin B, Redinbo MR, Kliewer SA. Regulation of cyp3a gene transcription by the pregnane x receptor. Annu Rev Pharmacol Toxicol 2002;42:1-23
142. Liu FJ, Song X, Yang D, et al. The far and distal enhancers in the CYP3A4 gene co-ordinate the proximal promoter in responding similarly to the pregnane X receptor but differentially to hepatocyte nuclear factor-4alpha. Biochem J 2008;409(1):243-250
143. Dolwick KM, Schmidt JV, Carver LA, et al. Cloning and expression of a human Ah receptor cDNA. Mol Pharmacol 1993;44(5):911-917
144. Carlson DB, Perdew GH. A dynamic role for the Ah receptor in cell signaling? Insights from a diverse group of Ah receptor interacting proteins. J Biochem Mol Toxicol 2002;16(6):317-325
145. Hankinson O. The aryl hydrocarbon receptor complex. Annu Rev Pharmacol Toxicol 1995;35:307-340
146. Mimura J, Fujii-Kuriyama Y. Functional role of AhR in the expression of toxic effects by TCDD. Biochim Biophys Acta 2003;1619(3):263-268
147. Androutsopoulos VP, Tsatsakis AM, Spandidos DA. Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention. BMC Cancer 2009;9:187
148. Corchero J, Pimprale S, Kimura S, Gonzalez FJ. Organization of the CYP1A cluster on human chromosome 15: implications for gene regulation. Pharmacogenetics 2001;11(1):1-6
149. Ueda R, Iketaki H, Nagata K, et al. A common regulatory region functions bidirectionally in transcriptional activation of the human CYP1A1 and CYP1A2 genes. Mol Pharmacol 2006;69(6):1924-1930
150. Kobayashi A, Sogawa K, Fujii-Kuriyama Y. Cooperative interaction between AhR.Arnt and Sp1 for the drug-inducible expression of CYP1A1 gene. J Biol Chem 1996;271(21):12310-12316
151. Kobayashi K, Sueyoshi T, Inoue K, et al. Cytoplasmic accumulation of the nuclear receptor CAR by a tetratricopeptide repeat protein in HepG2 cells. Mol Pharmacol 2003;64(5):1069-1075
152. Kawamoto T, Sueyoshi T, Zelko I, et al. Phenobarbital-responsive nuclear translocation of the receptor CAR in induction of the CYP2B gene. Mol Cell Biol 1999;19(9):6318-6322 (Pubitemid 29399336)
153. Xu RX, Lambert MH, Wisely BB, et al. A structural basis for constitutive activity in the human CAR/RXRalpha heterodimer. Mol Cell 2004;16(6):919-928
154. Suino K, Peng L, Reynolds R, et al. The nuclear xenobiotic receptor CAR: structural determinants of constitutive activation and heterodimerization. Mol Cell 2004;16(6):893-905
155. Hewitt NJ, Lecluyse EL, Ferguson SS. Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations. Xenobiotica 2007;37(10-11):1196-1224
156. Forman BM, Tzameli I, Choi HS, et al. Androstane metabolites bind to and deactivate the nuclear receptor CAR-beta. Nature 1998;395(6702):612-615
157. Moore LB, Parks DJ, Jones SA, et al. Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J Biol Chem 2000;275(20):15122-15127
158. Zelko I, Sueyoshi T, Kawamoto T, et al. The peptide near the C terminus regulates receptor CAR nuclear translocation induced by xenochemicals in mouse liver. Mol Cell Biol 2001;21(8):2838-2846
159. Yoshinari K, Kobayashi K, Moore R, et al. Identification of the nuclear receptor CAR:HSP90 complex in mouse liver and recruitment of protein phosphatase 2A in response to phenobarbital. FEBS Lett 2003;548(1-3):17-20
160. Koike C, Moore R, Negishi M. Extracellular signal-regulated kinase is an endogenous signal retaining the nuclear constitutive active/androstane receptor (CAR) in the cytoplasm of mouse primary hepatocytes. Mol Pharmacol 2007;71(5):1217-1221
161. Rencurel F, Foretz M, Kaufmann MR, et al. Stimulation of AMP-activated protein kinase is essential for the induction of drug metabolizing enzymes by phenobarbital in human and mouse liver. Mol Pharmacol 2006;70(6):1925-1934
162. Honkakoski P, Zelko I, Sueyoshi T, Negishi M. The nuclear orphan receptor CAR-retinoid X receptor heterodimer activates the phenobarbital-responsive enhancer module of the CYP2B gene. Mol Cell Biol 1998;18(10):5652-5658
163. Sueyoshi T, Kawamoto T, Zelko I, et al. The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. J Biol Chem 1999;274(10):6043-6046
164. Madan A, Graham RA, Carroll KM, et al. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 2003;31(4):421-431
165. Perrot N, Nalpas B, Yang CS, Beaune PH. Modulation of cytochrome P450 isozymes in human liver, by ethanol and drug intake. Eur J Clin Invest 1989;19(6):549-555
166. Gerbal-Chaloin S, Daujat M, Pascussi JM, et al. Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor. J Biol Chem 2002;277(1):209-217
167. Xu C, Li CY, Kong AN. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res 2005;28(3):249-268
168. Honkakoski P, Negishi M. Regulatory DNA elements of phenobarbital- responsive cytochrome P450 CYP2B genes. J Biochem Mol Toxicol 1998;12(1):3-9
169. Makinen J, Frank C, Jyrkkarinne J, et al. Modulation of mouse and human phenobarbital-responsive enhancer module by nuclear receptors. Mol Pharmacol 2002;62(2):366-378
170. Maglich JM, Stoltz CM, Goodwin B, et al. Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol Pharmacol 2002;62(3):638-646
171. Goodwin B, Moore LB, Stoltz CM, et al. Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol Pharmacol 2001;60(3):427-431 (Pubitemid 32781548)
172. Moore JT, Moore LB, Maglich JM, Kliewer SA. Functional and structural comparison of PXR and CAR. Biochim Biophys Acta 2003;1619(3):235-238
173. Goodwin B, Hodgson E, D'Costa DJ, et al. Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor. Mol Pharmacol 2002;62(2):359-365
174. Wang H, Faucette S, Sueyoshi T, et al. A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression. J Biol Chem 2003;278(16):14146-14152
175. Wortham M, Czerwinski M, He L, et al. Expression of constitutive androstane receptor, hepatic nuclear factor 4 alpha, and P450 oxidoreductase genes determines interindividual variability in basal expression and activity of a broad scope of xenobiotic metabolism genes in the human liver. Drug Metab Dispos 2007;35(9):1700-1710
176. Drewes T, Senkel S, Holewa B, Ryffel GU. Human hepatocyte nuclear factor 4 isoforms are encoded by distinct and differentially expressed genes. Mol Cell Biol 1996;16(3):925-931
177. Jiang S, Tanaka T, Iwanari H, et al. Expression and localization of P1 promoter-driven hepatocyte nuclear factor-4alpha (HNF4alpha) isoforms in human and rats. Nucl Recept 2003;1(1):5
178. Gonzalez FJ. Regulation of hepatocyte nuclear factor 4 alpha-mediated transcription. Drug Metab Pharmacokinet 2008;23(1):2-7
179. Wisely GB, Miller AB, Davis RG, et al. Hepatocyte nuclear factor 4 is a transcription factor that constitutively binds fatty acids. Structure 2002;10(9):1225-1234
180. Schroeder F, Huang H, Hostetler HA, et al. Stability of fatty acyl-coenzyme A thioester ligands of hepatocyte nuclear factor-4alpha and peroxisome proliferator-activated receptor-alpha. Lipids 2005;40(6):559-568
181. Kamiyama Y, Matsubara T, Yoshinari K, et al. Role of human hepatocyte nuclear factor 4alpha in the expression of drug-metabolizing enzymes and transporters in human hepatocytes assessed by use of small interfering RNA. Drug Metab Pharmacokinet 2007;22(4):287-298
182. Jover R, Bort R, Gomez-Lechon MJ, Castell JV. Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: a study using adenovirus-mediated antisense targeting. Hepatology 2001;33(3):668-675
183. Tirona RG, Lee W, Leake BF, et al. The orphan nuclear receptor HNF4alpha determines PXR-and CAR-mediated xenobiotic induction of CYP3A4. Nat Med 2003;9(2):220-224
184. Rana R, Chen Y, Ferguson S, et al. Hepatocyte nuclear factor 4{alpha} regulates rifampicin-mediated induction of CYP2C genes in primary cultures of human hepatocytes. Drug Metab Dispos 2010;38(4):591-599
185. Jones SA, Moore LB, Wisely GB, Kliewer SA. Use of in vitro pregnane X receptor assays to assess CYP3A4 induction potential of drug candidates. Methods Enzymol 2002;357:161-170
186. Zhu Z, Kim S, Chen T, et al. Correlation of high-throughput pregnane X receptor (PXR) transactivation and binding assays. J Biomol Screen 2004;9(6):533-540
187. Hewitt NJ, Lechon MJ, Houston JB, et al. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 2007;39(1):159-234
188. Plant N. Strategies for using in vitro screens in drug metabolism. Drug Discov Today 2004;9(7):328-336
189. Sandker GW, Weert B, Olinga P, et al. Characterization of transport in isolated human hepatocytes. A study with the bile acid taurocholic acid, the uncharged ouabain and the organic cations vecuronium and rocuronium. Biochem Pharmacol 1994;47(12):2193-2200
190. Silva JM, Morin PE, Day SH, et al. Refinement of an in vitro cell model for cytochrome P450 induction. Drug Metab Dispos 1998;26(5):490-496
191. Smith DA. Induction and drug development. Eur J Pharm Sci 2000;11(3):185-189
192. Roymans D, Annaert P, Van Houdt J, et al. Expression and induction potential of cytochromes P450 in human cryopreserved hepatocytes. Drug Metab Dispos 2005;33(7):1004-1016
193. LeCluyse EL. Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur J Pharm Sci 2001 13(4):343-368
194. LeCluyse E, Madan A, Hamilton G, et al. Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes. J Biochem Mol Toxicol 2000;14(4):177-188
195. Hamilton GA, Jolley SL, Gilbert D, et al. Regulation of cell morphology and cytochrome P450 expression in human hepatocytes by extracellular matrix and cell-cell interactions. Cell Tissue Res 2001;306(1):85-99
196. Rodriguez-Antona C, Donato MT, Boobis A, et al. Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. Xenobiotica 2002;32(6):505-520
197. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270(1):414-423
198. Parkinson A, Mudra DR, Johnson C, et al. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 2004;199(3):193-209
199. Thummel KE, Shen DD, Podoll TD, et al. Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter-and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 1994;271(1):557-566
200. Persson KP, Ekehed S, Otter C, et al. Evaluation of human liver slices and reporter gene assays as systems for predicting the cytochrome p450 induction potential of drugs in vivo in humans. Pharm Res 2006;23(1):56-69
201. Sinz M, Kim S, Zhu Z, et al. Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. Curr Drug Metab 2006;7(4):375-388
202. Westerink WM, Schoonen WG. Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicol In Vitro 2007;21(8):1581-1591
203. Moore LB, Maglich JM, McKee DD, et al. Pregnane X receptor (PXR), constitutive androstane receptor (CAR), and benzoate X receptor (BXR) define three pharmacologically distinct classes of nuclear receptors. Mol Endocrinol 2002;16(5):977-986
204. Faucette SR, Zhang TC, Moore R, et al. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther 2007;320(1):72-80
205. van Giersbergen PL, Gnerre C, Treiber A, et al. Bosentan, a dual endothelin receptor antagonist, activates the pregnane X nuclear receptor. Eur J Pharmacol 2002;450(2):115-121
206. Donato MT, Lahoz A, Castell JV, Gomez-Lechon MJ. Cell lines: a tool for in vitro drug metabolism studies. Curr Drug Metab 2008;9(1):1-11
207. Gripon P, Rumin S, Urban S, et al. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci USA 2002;99(24):15655-15660
208. Aninat C, Piton A, Glaise D, et al. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos 2006;34(1):75-83
209. Kanebratt KP, Andersson TB. HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. Drug Metab Dispos 2008 36(1):137-145
210. Josse R, Aninat C, Glaise D, et al. Long-term functional stability of human HepaRG hepatocytes and use for chronic toxicity and genotoxicity studies. Drug Metab Dispos 2008 36(6):1111-1118
211. Martin H, Sarsat JP, de Waziers I, et al. Induction of cytochrome P450 2B6 and 3A4 expression by phenobarbital and cyclophosphamide in cultured human liver slices. Pharm Res 2003;20(4):557-568
212. Edwards RJ, Price RJ, Watts PS, et al. Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab Dispos 2003;31(3):282-288
213. Tateno C, Yoshizane Y, Saito N, et al. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 2004;165(3):901-912
214. Emoto C, Yamato Y, Sato Y, et al. Non-invasive method to detect induction of CYP3A4 in chimeric mice with a humanized liver. Xenobiotica 2008;38(3):239-248
215. Katoh M, Tateno C, Yoshizato K, Yokoi T. Chimeric mice with humanized liver. Toxicology 2008;246(1):9-17
216. Azuma H, Paulk N, Ranade A, et al. Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/-mice. Nat Biotechnol 2007;25(8):903-910
217. Kato M, Chiba K, Horikawa M, Sugiyama Y. The quantitative prediction of in vivo enzyme-induction caused by drug exposure from in vitro information on human hepatocytes. Drug Metab Pharmacokinet 2005;20(4):236-243
218. Fahmi OA, Boldt S, Kish M, et al. Prediction of drug-drug interactions from in vitro induction data: application of the relative induction score approach using cryopreserved human hepatocytes. Drug Metab Dispos 2008;36(9):1971-1974
219. Kozawa M, Honma M, Suzuki H. Quantitative prediction of in vivo profiles of CYP3A4 induction in humans from in vitro results with a reporter gene assay. Drug Metab Dispos 2009;37(6):1234-1241
220. Kostrubsky VE, Ramachandran V, Venkataramanan R, et al. The use of human hepatocyte cultures to study the induction of cytochrome P-450. Drug Metab Dispos 1999;27(8):887-894
221. Chang TK, Yu L, Maurel P, Waxman DJ. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res 1997;57(10):1946-1954
222. Renwick AB, Watts PS, Edwards RJ, et al. Differential maintenance of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab Dispos 2000;28(10):1202-1209
223. Fromm MF, Busse D, Kroemer HK, Eichelbaum M. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 1996;24(4):796-801
224. Hsu A, Granneman GR, Witt G, et al. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 1997;41(5):898-905
225. Lai AA, Levy RH, Cutler RE. Time-course of interaction between carbamazepine and clonazepam in normal man. Clin Pharmacol Ther 1978;24(3):316-323
226. Faucette SR, Sueyoshi T, Smith CM, et al. Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor. J Pharmacol Exp Ther 2006;317(3):1200-1209
227. Wang H, Faucette S, Moore R, et al. Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin. J Biol Chem 2004;279(28):29295-29301
228. O'Reilly RA. Interaction of chronic daily warfarin therapy and rifampin. Ann Intern Med 1975;83(4):506-508
229. Grub S, Bryson H, Goggin T, et al. The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients. Eur J Clin Pharmacol 2001;57(2):115-121
230. la Porte CJ, Colbers EP, Bertz R, et al. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 2004;48(5):1553-1560
231. Lau WC, Gurbel PA. Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4. Pharm Res 2006;23(12):2691-2708
232. Ernest CS II, Hall SD, Jones DR. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 2005;312(2):583-591
233. McGinnity DF, Zhang G, Kenny JR, et al. Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cells. Drug Metab Dispos 2009;37(6):1259-1268
234. Liu P, Foster G, Gandelman K, et al. Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. Antimicrob Agents Chemother 2007;51(10):3617-3626
235. Yakiwchuk EM, Foisy MM, Hughes CA. Complexity of interactions between voriconazole and antiretroviral agents. Ann Pharmacother 2008;42(5):698-703
236. LeCluyse EL, Fix JA, Audus KL, Hochman JH. Regeneration and maintenance of bile canalicular networks in collagen-sandwiched hepatocytes. Toxicol In Vitro 2000;14(2):117-132
237. Kostrubsky VE, Lewis LD, Strom SC, et al. Induction of cytochrome P4503A by taxol in primary cultures of human hepatocytes. Arch Biochem Biophys 1998;355(2):131-136
238. Masubuchi N, Li AP, Okazaki O. An evaluation of the cytochrome P450 induction potential of pantoprazole in primary human hepatocytes. Chem Biol Interact 1998;114(1-2):1-13
239. Hassett C, Laurenzana EM, Sidhu JS, Omiecinski CJ. Effects of chemical inducers on human microsomal epoxide hydrolase in primary hepatocyte cultures. Biochem Pharmacol 1998;55(7):1059-1069
240. Martinez-Jimenez CP, Castell JV, Gomez-Lechon MJ, Jover R. Transcriptional activation of CYP2C9, CYP1A1, and CYP1A2 by hepatocyte nuclear factor 4alpha requires coactivators peroxisomal proliferator activated receptor-gamma coactivator 1alpha and steroid receptor coactivator 1. Mol Pharmacol 2006;70(5):1681-1692
241. Dixit V, Hariparsad N, Li F, et al. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos 2007;35(10):1853-1859
242. Bachleda P, Vrzal R, Pivnicka J, et al. Examination of Zolpidem effects on AhR-and PXR-dependent expression of drug-metabolizing cytochromes P450 in primary cultures of human hepatocytes. Toxicol Lett 2009;191(1):74-78
243. Maglich JM, Parks DJ, Moore LB, et al. Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. J Biol Chem 2003;278(19):17277-17283
244. Rae JM, Johnson MD, Lippman ME, Flockhart DA. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther 2001;299(3):849-857
245. Jigorel E, Le Vee M, Boursier-Neyret C, et al. Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab Dispos 2006;34(10):1756-1763
246. Sahi J, Shord SS, Lindley C, et al. Regulation of cytochrome P450 2C9 expression in primary cultures of human hepatocytes. J Biochem Mol Toxicol 2009;23(1):43-58
247. Ferguson SS, Chen Y, LeCluyse EL, et al. Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4alpha. Mol Pharmacol 2005;68(3):747-757 (Pubitemid 41206028)
248. Raucy JL, Mueller L, Duan K, et al. Expression and induction of CYP2C P450 enzymes in primary cultures of human hepatocytes. J Pharmacol Exp Ther 2002;302(2):475-482
249. Chen Y, Kissling G, Negishi M, Goldstein JA. The nuclear receptors constitutive androstane receptor and pregnane X receptor cross-talk with hepatic nuclear factor 4alpha to synergistically activate the human CYP2C9 promoter. J Pharmacol Exp Ther 2005;314(3):1125-1133
250. Li T, Chiang JY. Rifampicin induction of CYP3A4 requires pregnane X receptor cross talk with hepatocyte nuclear factor 4alpha and coactivators, and suppression of small heterodimer partner gene expression. Drug Metab Dispos 2006;34(5):756-764
251. Assem M, Schuetz EG, Leggas M, et al. Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J Biol Chem 2004;279(21):22250-22257
252. Fang HL, Strom SC, Ellis E, et al. Positive and negative regulation of human hepatic hydroxysteroid sulfotransferase (SULT2A1) gene transcription by rifampicin: roles of hepatocyte nuclear factor 4alpha and pregnane X receptor. J Pharmacol Exp Ther 2007;323(2):586-598
253. Li L, Stanton JD, Tolson AH, et al. Bioactive terpenoids and flavonoids from Ginkgo biloba extract induce the expression of hepatic drug-metabolizing enzymes through pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor-mediated pathways. Pharm Res 2009;26(4):872-882
254. Kast HR, Goodwin B, Tarr PT, et al. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 2002;277(4):2908-2915
255. Peamkrasatam S, Sriwatanakul K, Kiyotani K, et al. In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais. Drug Metab Pharmacokinet 2006;21(6):475-484
256. Elsherbiny DA, Asimus SA, Karlsson MO, et al. A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens. J Pharmacokinet Pharmacodyn 2008;35(2):203-217
257. Simonsson US, Jansson B, Hai TN, et al. Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9. Clin Pharmacol Ther 2003;74(1):32-43
258. Svensson US, Ashton M, Trinh NH, et al. Artemisinin induces omeprazole metabolism in human beings. Clin Pharmacol Ther 1998;64(2):160-167
259. Dingemanse J, van Giersbergen PL. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet 2004;43(15):1089-1115
260. Parker AC, Pritchard P, Preston T, Choonara I. Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath test. Br J Clin Pharmacol 1998;45(2):176-178
261. Herman D, Locatelli I, Grabnar I, et al. The influence of co-treatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose. Eur J Clin Pharmacol 2006;62(4):291-296
262. Ketter TA, Jenkins JB, Schroeder DH, et al. Carbamazepine but not valproate induces bupropion metabolism. J Clin Psychopharmacol 1995;15(5):327-333
263. Backman JT, Olkkola KT, Ojala M, et al. Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia 1996;37(3):253-257
264. Furukori H, Otani K, Yasui N, et al. Effect of carbamazepine on the single oral dose pharmacokinetics of alprazolam. Neuropsychopharmacology 1998;18(5):364-369
265. McCune JS, Hawke RL, LeCluyse EL, et al. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther 2000;68(4):356-366
266. Fellay J, Marzolini C, Decosterd L, et al. Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. Eur J Clin Pharmacol 2005;60(12):865-873
267. Faber MS, Jetter A, Fuhr U. Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin Pharmacol Toxicol 2005;97(3):125-134
268. Reed GA, Peterson KS, Smith HJ, et al. A phase I study of indole-3-carbinol in women: tolerability and effects. Cancer Epidemiol Biomarkers Prev 2005;14(8):1953-1960
269. Ma Q, Lu AY. CYP1A induction and human risk assessment: an evolving tale of in vitro and in vivo studies. Drug Metab Dispos 2007;35(7):1009-1016
270. Gerber JG, Rosenkranz SL, Fichtenbaum CJ, et al. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defic Syndr 2005;39(3):307-312
271. Huuskonen P, Storvik M, Reinisalo M, et al. Microarray analysis of the global alterations in the gene expression in the placentas from cigarette-smoking mothers. Clin Pharmacol Ther 2008;83(4):542-550
272. Chang TK, Chen J, Pillay V, et al. Real-time polymerase chain reaction analysis of CYP1B1 gene expression in human liver. Toxicol Sci 2003;71(1):11-19
273. Landay RA, Gonzalez MA, Taylor JC. Effect of phenobarbital on theophylline disposition. J Allergy Clin Immunol 1978;62(1):27-29
274. Jao JY, Jusko WJ, Cohen JL. Phenobarbital effects on cyclophosphamide pharmacokinetics in man. Cancer Res 1972;32(12):2761-2764
275. Heinemeyer G, Gramm HJ, Simgen W, et al. Kinetics of hexobarbital and dipyrone in critical care patients receiving high-dose pentobarbital. Eur J Clin Pharmacol 1987;32(3):273-277
276. Back DJ, Bates M, Bowden A, et al. The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy. Contraception 1980;22(5):495-503
277. Miller M, Cosgriff J, Kwong T, Morken DA. Influence of phenytoin on theophylline clearance. Clin Pharmacol Ther 1984;35(5):666-669
278. Slattery JT, Kalhorn TF, McDonald GB, et al. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J Clin Oncol 1996;14(5):1484-1494
279. Lim ML, Min SS, Eron JJ, et al. Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J Acquir Immune Defic Syndr 2004;36(5):1034-1040
280. Backman JT, Granfors MT, Neuvonen PJ. Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine. Eur J Clin Pharmacol 2006;62(6):451-461
281. Loboz KK, Gross AS, Williams KM, et al. Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. Clin Pharmacol Ther 2006;80(1):75-84
282. Bidstrup TB, Stilling N, Damkier P, et al. Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. Eur J Clin Pharmacol 2004;60(2):109-114
283. Jaakkola T, Backman JT, Neuvonen M, et al. Effect of rifampicin on the pharmacokinetics of pioglitazone. Br J Clin Pharmacol 2006;61(1):70-78
284. Park JY, Kim KA, Kang MH, et al. Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. Clin Pharmacol Ther 2004;75(3):157-162
285. Niemi M, Backman JT, Fromm MF, et al. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003;42(9):819-850
286. Niemi M, Backman JT, Neuvonen M, et al. Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin Pharmacol Ther 2001;69(6):400-406 (Pubitemid 32554545)
287. Kanebratt KP, Diczfalusy U, Backstrom T, et al. Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol. Clin Pharmacol Ther 2008;84(5):589-594
288. Holtbecker N, Fromm MF, Kroemer HK, et al. The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. Drug Metab Dispos 1996;24(10):1121-1123
289. Niemi M, Backman JT, Neuvonen M, et al. Rifampin decreases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther 2000;68(5):495-500
290. Villikka K, Kivisto KT, Luurila H, Neuvonen PJ. Rifampin reduces plasma concentrations and effects of zolpidem. Clin Pharmacol Ther 1997;62(6):629-634
291. Yeh RF, Gaver VE, Patterson KB, et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 2006;42(1):52-60
292. Kharasch ED, Mitchell D, Coles R, Blanco R. Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. Antimicrob Agents Chemother 2008;52(5):1663-1669
293. Jiang X, Blair EY, McLachlan AJ. Investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach. J Clin Pharmacol 2006;46(11):1370-1378
294. Wang LS, Zhou G, Zhu B, et al. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther 2004;75(3):191-197
295. Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003;290(11):1500-1504
296. Dresser GK, Schwarz UI, Wilkinson GR, Kim RB. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin Pharmacol Ther 2003;73(1):41-50
297. Birkett DJ, Miners JO, Attwood J. Evidence for a dual action of sulphinpyrazone on drug metabolism in man: theophylline-sulphinpyrazone interaction. Br J Clin Pharmacol 1983;15(5):567-569
298. Wing LM, Miners JO, Lillywhite KJ. Verapamil disposition-effects of sulphinpyrazone and cimetidine. Br J Clin Pharmacol 1985;19(3):385-391
299. Yoshinari K, Yoda N, Toriyabe T, Yamazoe Y. Constitutive androstane receptor transcriptionally activates human CYP1A1 and CYP1A2 genes through a common regulatory element in the 5¢-flanking region. Biochem Pharmacol 2010;79(2):261-269
300. Tsuchiya Y, Nakajima M, Yokoi T. Critical enhancer region to which AhR/ARNT and Sp1 bind in the human CYP1B1 gene. J Biochem 2003;133(5):583-592
301. Chen Y, Ferguson SS, Negishi M, Goldstein JA. Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter. Mol Pharmacol 2003;64(2):316-324